Search

Hauser, RA, V Abler, E Eyal, and RE Eliaz. 2016. “Efficacy of Rasagiline in Early Parkinson’s Disease: A Meta-Analysis of Data from the TEMPO and ADAGIO Studies. Int J Neurosci 2016;126:942-6.”. Int J Neurosci.

Francois, C, RA Hauser, S Aballea, J Dorey, E Kharitonova, and Arthur Hewitt. 2016. “Cost-Effectiveness of Droxidopa in Patients With Neurogenic Orthostatic Hypotension: Post-Hoc Economic Analysis of Phase 3 Clinical Trial Data. J Med Econ 2016;19:515-25.”. J Med Econ.

Seeberger, LC, and RA Hauser. 2016. “Seeberger LC, Hauser RA.Carbidopa Levodopa Enteral Suspension. Expert Opin Pharmacother 2015;16:2807-17.”. Expert Opin Pharmacother.

“Hauser RA. Help Cure Parkinson’s Disease: Please Don’t Waste the Golden Year. NPJ Parkinsons Dis 2018;4:29.”. 2018. NPJ Parkinsons Dis.

Schapira, AH, SH Fox, RA Hauser, J Jankovic, WH Jost, C Kennedy, J Kulisevsky, R Pahwa, W Poewe, and R Anand. 2017. “Assessment of Safety and Efficacy of Safinamide As a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.”. JAMA Neurol.

White, WB, RA Hauser, GJ Rowse, A Ziemann, and LA Hewitt. 2017. “Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.”. Am J Cardiol.

Biglan, KM, D Oakes, AE Lang, RA Hauser, K Hodgeman, B Greco, J Lowell, et al. 2017. “A Novel Design of a Phase III Trial of Isradipine in Early Parkinson Disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.”. Ann Clin Transl Neurol.

Hauser, RA, S Isaacson, JP Lisk, LA Arthur Hewitt, and G Rowse. 2015. “Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson’s Disease (nOH306B). Mov Disord 2015;30:646-54.”. Mov Disord.

Wechsler, R, RA Hauser, and J French. 2015. “Who Is Helping Whom? Manuscript Support and Transfer of Value. Ann Neurol 2015;77:353-5.”. Ann Neurol.

Simon, DK, C Wu, BC Tilley, AM Wills, MJ Aminoff, J Bainbridge, RA Hauser, et al. 2015. “Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.”. Clin Neuropharmacol.